Latest:
Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL
Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Rebecca A. Shatsky, MD
Latest:
Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.
Hans Wildiers, MD
Latest:
Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer
Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.
Cancer Treatment Centers of America
Latest:
Cancer Treatment Centers of America Grows Medical Oncologist Roster Across Hospitals
Medical oncologists Dr. Ajaz Khan, Dr. Ryan Engel, and Dr. Nitika Sharma are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America®.
Dan Lodder, MBA
Latest:
The Future of Reimbursement: How AI Can Revolutionize Oncology Practices
By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.
Neil Desai, MD
Latest:
Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBC
Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.
Mitchell E. Horwitz, MD
Latest:
Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD
The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.
VCU Massey Cancer Center
Latest:
Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be Lower
Survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.
Courtney Marabella
Senior Editor,
Latest:
Addition of Dalpiciclib to Fulvestrant Improves PFS in HR+ Advanced Breast Cancer
The addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.